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Vascular endothelial growth factor (VEGF)
expression in locally advanced prostate cancer:
secondary analysis of radiation therapy oncology
group (RTOG) 8610
Larry Pan1*, Seunghee Baek2, Pamela R Edmonds3, Mack Roach III4, Harvey Wolkov5, Satish Shah6, Alan Pollack7,
M Elizabeth Hammond8 and Adam P Dicker9
Abstract
Background: Angiogenesis is a key element in solid-tumor growth, invasion, and metastasis. VEGF is among the
most potent angiogenic factor thus far detected. The aim of the present study is to explore the potential of VEGF
(also known as VEGF-A) as a prognostic and predictive biomarker among men with locally advanced prostate
cancer.
Methods: The analysis was performed using patients enrolled on RTOG 8610, a phase III randomized control trial of
radiation therapy alone (Arm 1) versus short-term neoadjuvant and concurrent androgen deprivation and radiation
therapy (Arm 2) in men with locally advanced prostate carcinoma. Tissue samples were obtained from the RTOG
tissue repository. Hematoxylin and eosin slides were reviewed, and paraffin blocks were immunohistochemically
stained for VEGF expression and graded by Intensity score (0–3). Cox or Fine and Gray’s proportional hazards
models were used.
Results: Sufficient pathologic material was available from 103 (23%) of the 456 analyzable patients enrolled in the
RTOG 8610 study. There were no statistically significant differences in the pre-treatment characteristics between the
patient groups with and without VEGF intensity data. Median follow-up for all surviving patients with VEGF intensity
data is 12.2 years. Univariate and multivariate analyses demonstrated no statistically significant correlation between
the intensity of VEGF expression and overall survival, distant metastasis, local progression, disease-free survival, or
biochemical failure. VEGF expression was also not statistically significantly associated with any of the endpoints
when analyzed by treatment arm.
Conclusions: This study revealed no statistically significant prognostic or predictive value of VEGF expression for
locally advanced prostate cancer. This analysis is among one of the largest sample bases with long-term follow-up
in a well-characterized patient population. There is an urgent need to establish multidisciplinary initiatives for
coordinating further research in the area of human prostate cancer biomarkers.
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Introduction
Prostate cancer represents the most common malignancy
and the second leading cause of cancer-related death in
American men over the age of 40 years [1]. The majority
of deaths secondary to prostate cancer are from metastases
as a result of lymphatic or hematogenous dissemination
of tumor cells. Angiogenesis, the development of new
vessels from existing vasculature, is a key element in
solid-tumor growth, invasion, and metastasis [2,3]. A
balance of proangiogenic and antiangiogenic factors tightly
controls physiologic angiogenesis to achieve homeostasis.
A tipping of this balance towards pro-angiogenesis,
termed the “angiogenic switch”, occurs with inflammation,
tissue hypoxia, or neoplasia [3,4].
Vascular endothelial growth factor (VEGF) is among
the most potent angiogenic factor thus far detected and
has been found to be highly specific for endothelial cells
in vitro and in vivo, promoting endothelial cell prolif-
eration and increasing vascular permeability [5-9].
VEGF is a 45 kDa heparin-binding polypeptide of the
platelet-derived growth factor family and is secreted
by a variety of malignant cells. It has been shown to
be expressed in many different types of tumors, including
renal cell carcinoma, breast carcinoma, gliomas, and hepa-
tocellular carcinoma [10-13].
By diffusion of oxygen and metabolites from local
vessels, tumor cells can survive only up to a tumor
diameter of 2–3 mm, beyond which new vessel
formation is required [14]. As a result of the ensuing
hypoxia, hypoxia inducible factor 1-alpha (HIF-1a)
stabilizes and translocates to the nucleus to bind
with HIF-1b forming HIF. This latter transcription
factor then stimulates VEGF production, resulting in
angiogenesis and the development of new vessels
into the tumor [3,4,15,16]. Recently, it has also been
suggested that androgen deprivation therapy may
result in increased VEGF expression, suggesting the
potential utility of VEGF-based anti-angiogenic agents
together with androgen deprivation in the manage-
ment of advanced prostate cancer [17]. The VEGF
expression of a tumor may thus potentially have
prognostic and predictive value for patient outcomes and
tumor specific therapies.
Although VEGF expression in prostate adenocarcinoma
has been shown to be expressed by immunohistochemical
(IHC) analysis in various studies, the results in the
literature have been markedly variable, with prior
studies reporting VEGF expression in approximately
40% to 100% of prostate cancer cases [18-28]. The
aim of the present study is to explore the potential
value of VEGF as a prognostic and predictive biomarker
among men with locally advanced prostate cancer
enrolled on a phase III trial in the Radiation Therapy
Oncology Group (RTOG), RTOG 8610.
Methods
Study population
The analysis was performed using patients enrolled on
RTOG 8610 [29] (“a phase III trial of goserelin and
flutamide used as cytoreductive agents in locally advanced
carcinoma of the prostate treated with definitive
radiotherapy”), which closed in 1991 with a total of 471
patients entered; 456 of the patients were assessable.
Patients received short-term androgen deprivation
therapy (STAD) consisting of 4 months of hormonal
therapy given neoadjuvantly and concurrently with
radiation therapy (RT), or they received RT alone.
Results from the trial demonstrated a statistically
significant improvement in 10-year biochemical failure
(65% vs. 80%; p < 0.0001), disease-free survival (11%
vs. 3%; p < 0.0001), disease-specific mortality (23% vs.
36%; p = 0.01), and distant metastasis (35% vs. 47%;
p = 0.006) with the addition of STAD. Diagnostic material
(from needle biopsies or transurethral resections) was
reviewed centrally for 461 (98%) of the 471 patients by the
study pathologist (D. J. Grignon, Wayne State University),
and the tumors were graded according to the criteria
of Gleason [30]. Tissue blocks were requested from
participating institutions (>100) at the time of central
pathology review for all cases that were reviewed. For
the present retrospective study, a subset of the patients
with sufficient pathologic material available entered in the
RTOG 8610 protocol was evaluated for VEGF expression
(103 patients). Specimens on all available individual
patients enrolled on the RTOG 8610 protocol were
obtained from the RTOG tissue repository.
Immunohistochemical (IHC) analysis
Formalin-fixed, paraffin-embedded tissue from the pre-
treatment diagnostic biopsies was sectioned and stored
at 4°C, for more than 5 years in the majority of cases,
before being processed for IHC staining. The paraffin
blocks were used to prepare the Hematoxylin and Eosin
stained slides. These slides were reviewed by one of the in-
vestigators (E.H.) to select regions of invasive tumor with-
out inflammation or necrosis. Regions with such tumor
areas were outlined with a cytology marking pen. Subse-
quent sections for use in immunohistochemistry were
cut at 4 microns. For inclusion in the study, the stained
section had to contain identifiable carcinoma. Positive
control tissues for each reaction were also cut onto the
test slide (kidney tissue), so that positive control and slide
to be tested were simultaneously stained. Unstained
sections were used in a standard IHC assay for VEGF
involving heat induced epitope retrieval for 20 minutes,
followed by antibody incubation with goat polyclonal
VEGF antibody (RD systems, catalogue #AF-293-NA) at
1:20 for 30 minutes followed by labeled streptavidin biotin
(LSAB) detection using Diaminobenzidine as substrate.
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The IHC procedure was done on a DAKO autostainer
(DAKO, Inc, Carpenteria, CA).
Three investigators (E.H., P.E. and A.D.) reviewed all
slides and recorded results without knowledge of patient
outcome. Consensus was achieved on the scoring. Scale
of 0-3+ was used to grade intensity of cytoplasmic staining
relative to the staining of the control kidney tissue. Dark
cytoplasmic staining was considered 3+. Weak staining
was pale staining relative to kidney control and 2+ staining
was any intensity between weak and strong staining. This
is a conventional scale for intensity measurement used for
most antigens. For statistical analysis, grades 0 and 1 were
considered as negative, whereas grades 2 and 3 as positive.
Definition of outcomes
The endpoints used in the analysis were per the RTOG
8610 protocol: overall survival (OS), local progression
(LP), distant metastasis (DM), biochemical failure (BF),
and disease-free survival (DFS). The failure event for
overall survival was defined as death due to any cause.
The overall survival time is measured from the date of
randomization to the date of death or the date of last
follow-up (censored). A local progression event is
defined as an increase of more than 50% in tumor size
(cross-sectional area), recurrence of a palpable tumor
after initial clearance, or biopsy specimen revealing
adenocarcinoma of the prostate two years or more after
study entry. A distant metastasis event is defined as the
clinical or radiographic evidence of disease beyond the
pelvis while regional metastasis is a clinical or radiographic
evidence of tumor in the pelvis with or without palpable
tumor in prostate by digital rectal examination. Time to a
distant and a local progression is measured from the date
of randomization to the occurrence of either event or
to the date of the most recent follow-up. Biochemical
failure is defined as a PSA of > 1.5 ng/ml one year
post-randomization. Time to biochemical failure is from
the one year post-randomization date to a failure date. A
failure in disease-free survival is defined as death due to
any cause, local progression, biochemical failure, regional
metastasis, or distant metastasis. Time to a disease-free
survival is measured from the date of randomization to
the earliest occurrence of all failure events or the most
recent follow-up.
Statistical analysis
VEGF expression intensity score data were dichotomized
as follows: Negative (VEGF = 0–1) vs. Positive (VEGF =
2–3). The following covariates were considered in the
multivariate analyses (MVA’s): age (<71 vs. ≥71), assigned
treatment (RT vs. STAD + RT), Gleason Score (2–6
vs. 7–10), and clinical T-stage (T2 vs. T3). The Cox
proportional hazard models were used for OS and
DFS, or Fine and Gray’s proportional hazards models
were used for LP, BF, and DM to examine if VEGF
expression is associated with patient outcomes with
and without covariates. These analyses were also
performed by treatment group to see the predictive
value of VEGF. The pre-treatment characteristics and
outcomes were compared between the patient groups
with and without missing VEGF values and between
the VEGF negative and positive groups by Chi-square
test statistics. Unadjusted and adjusted hazard ratios
(HRs) were calculated for all covariates using either
the Cox proportional hazard model or Fine and
Gray’s regression model with 95% confidence intervals
and p-values. All statistical tests were done at significance
level of 0.05. R software was used for Fine and Gray’s
model whereas Statistical Analysis System (SAS Institute,
Car, NC) was used for the rest of the analyses.
Results
From the RTOG tissue repository, tissue samples were
obtained from 103 (23%) of the 456 analyzable patients
enrolled in the RTOG 8610 study. All had pre-treatment
Table 1 Pre-treatment characteristics by VEGF intensity
score (n = 103)
Negative VEGF
intensity (0–1)
Positive VEGF
intensity (2–3)
(n = 48) (n = 55)
Characteristics n % n % p-value*
Age
Median 71.5 71
Range 55 – 77 55 – 81
<71 21 44 27 49 0.588*
≥71 27 56 28 51
Assigned Treatment
STAD + RT arm 22 46 23 42 0.682
RT alone arm 26 54 32 58
Combined Gleason Score
Missing 0 0 1 2
2-6 14 29 11 20 0.303**
7-10 34 71 43 78
Clinical Stage
T2 14 29 12 22 0.392*
T3 34 71 43 78
Failures
Overall Survival 39 81 51 93
Distant Metastasis 25 52 31 56
Local Progression 21 44 26 47
Disease-free Survival 48 100 54 98
Biochemical Failure 37 77 40 73
*p-value is from Chi-square test.
** p-value does not include unknown/missing category.
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Table 2 Multivariate proportional hazards models (n = 103)
Endpoints Covariate Comparison HR* 95% CI p-value**
Overall Survival VEGF 0-1 vs. RL
2-3 1.314 (0.850, 2.030) 0.219
Treatment arm STAD + RT arm vs. RL
RT alone arm 1.268 (0.821, 1.959) 0.285
Age < 71 vs. RL
≥ 71 1.708 (1.112, 2.625) 0.015†
Combined Gleason Score 2-6 vs. RL
7-10 1.416 (0.883, 2.270) 0.149
Clinical Stage T2 vs. RL
T3 1.026 (0.626, 1.681) 0.918
Distant Metastasis VEGF 0-1 vs. RL
2-3 1.090 (0.629, 1.889) 0.760
Treatment arm STAD + RT arm vs. RL
RT alone arm 1.472 (0.861, 2.517) 0.160
Age < 71 vs. RL
≥71 1.096 (0.631, 1.903) 0.740
Combined Gleason Score 2-6 vs. RL
7-10 2.528 (1.358, 4.705) 0.003†
Clinical Stage T2 vs. RL
T3 0.819 (0.446, 1.504) 0.520
Local Progression VEGF 0-1vs. RL
2-3 1.160 (0.662, 2.030) 0.600
Treatment arm STAD + RT arm vs. RL
RT alone arm 1.306 (0.726, 2.349) 0.370
Age < 71 vs. RL
≥71 0.873 (0.496, 1.536) 0.640
Combined Gleason Score 2-6 vs. RL
7-10 0.757 (0.426, 1.344) 0.340
Clinical Stage T2 vs. RL
T3 0.657 (0.361, 1.197) 0.170
Disease-free Survival VEGF 0-1vs. RL
2-3 0.859 (0.573, 1.286) 0.461
Treatment arm STAD + RT arm vs. RL
RT alone arm 2.102 (1.370, 3.227) < 0.001†
Age < 71 vs. RL
≥ 71 0.932 (0.618, 1.407) 0.738
Combined Gleason Score 2-6 vs. RL
7-10 1.717 (1.048, 2.813) 0.032†
Clinical Stage T2 vs. RL
T3 0.887 (0.539, 1.458) 0.626
Biochemical Failure VEGF 0-1vs. RL
2-3 1.041 (0.655, 1.652) 0.870
Treatment arm STAD + RT arm vs. RL
RT alone arm 1.995 (1.250, 3.186) 0.004†
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characteristics available for analysis. The majority of
patients had a clinical tumor stage T3 (75% of patients)
and T2 for the remaining 25% of patients. Seventy-five
percent of patients had Gleason Score (GS) 7–10, 24%
had GS 2–6, and 1% unknown/missing. Fifty-three
percent of patients were 71 years old or greater. There
were no statistically significant differences in the
pre-treatment characteristics between the patient groups
with and without VEGF intensity data (not shown).
Median follow-up for all surviving patients with VEGF
intensity data is 12.2 years. A negative VEGF intensity
score (0–1) was found in 47% of patients while a
positive VEGF intensity score (2–3) was found in 53%.
The distribution of VEGF intensity score was well
balanced between treatment arms. In the RT alone arm,
45% and 55% of patients had a VEGF intensity score of
0–1 and 2–3, respectively, while in the STAD + RT arm,
49% and 51% had a VEGF intensity score of 0–1 and 2–3,
respectively.
Table 1 illustrates the pre-treatment characteristics of
patients who are eligible and with VEGF intensity score.
There are no statistically significant differences between
the VEGF negative and positive groups with respect to
the pre-treatment characteristics.
Table 2 reports the multivariate proportional hazards
analyses for VEGF expression for each endpoint. As
presented in the table, the results, when adjusted for
other covariates, also show no significant association of
VEGF expression with any of the endpoints. Table 3
reports the results of proportional hazards regression by
treatment arm. VEGF expression was not significantly
associated with any of the endpoints for each arm,
although it appeared to be approaching statistical
significance with a p-value of 0.05 for disease-free survival
for the STAD + RT arm. Univariate and multivariate
analyses demonstrated no statistically significant correlation
between the intensity of VEGF expression (0–1) and (2–3)
for overall survival, distant metastasis, local progression,
disease-free survival, or biochemical failure. Figures 1, 2,
3, 4 and 5 illustrate the graphs for the univariate
proportional hazards regression models for each of the
above endpoints, portraying the non-statistical significance
of VEGF expression for these endpoints studied.
Discussion
The present study represents one of the largest sample
bases with long-term follow-up reviewed for VEGF expres-
sion in human prostate carcinoma patients, providing
much needed incremental progress in the field of under-
standing angiogenic factors and modern biomarkers for
prostate cancer prognosis, which to date has only been in-
vestigated in a limited number of studies. Although VEGF
expression has been well-studied in many other malignan-
cies, much controversy exists in the literature for VEGF
expression and its prognostic and predictive value for
prostate carcinoma [18-28,31-34]. The need for further
understanding in this area of prostate cancer research is
thus urgently needed.
The natural history of prostate carcinoma is one with
a wide spectrum, ranging from being relatively indolent
where a patient may have a life expectancy similar to
the general population, to being aggressive with rapid
development of metastases and ultimately death [35,36].
Currently, with conventional strategies, clinicians have only
a moderate ability to estimate prognosis in patients with
newly diagnosed prostate cancer, and subsequently there
is uncertainty regarding the optimal patient management.
These conventional prognostic indicators include
clinical tumor stage, Gleason score, and pre-treatment
serum prostate specific antigen (PSA) levels [37]. The
development of novel prognostic and predictive bio-
markers is thus crucial to identify patients who may
benefit from further specific therapy. A prognostic
biomarker furnishes information regarding the patient’s
overall cancer outcome, irrespective of therapy, while a
predictive biomarker may predict response to a particular
treatment [38].
Although commonly used tests for women with newly
diagnosed breast cancer include estrogen and progesterone
receptors and HER2 status, which have both prognostic
Table 2 Multivariate proportional hazards models (n = 103) (Continued)
Age < 71 vs. RL
≥ 71 0.770 (0.483, 1.229) 0.270
Combined Gleason Score 2-6 vs. RL
7-10 1.403 (0.785, 2.508) 0.250
Clinical Stage T2 vs. RL
T3 0.961 (0.503, 1.837) 0.900
* A hazard ratio (HR) is defined as the ratio of the estimated hazard for those with a variable value 1 to the estimated hazard for those with a variable value 0. A
hazard ratio of 1 indicates no difference between two subgroups.
** P-values from Chi-square test using Cox (overall survival and disease-free survival) or Fine & Gray (distant metastasis, local progression, and biochemical failure)
Proportional Hazards Model.
† indicates the statistically significant at the significance level of 0.05.
1 patient without Gleason score is not included.
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Table 3 Multivariate proportional hazards models by treatment arm
STAD + RT Arm(n = 45) Endpoints Covariate Comparison HR* 95% CI p-value**
Overall Survival VEGF 0-1 vs. RL (0.734, 2.745) 0.299
2-3 1.419
Age < 71 vs. RL (0.608, 2.910) 0.475
≥ 71 1.330
Combined Gleason Score 2-6 vs. RL (0.393, 2.581) 0.988
7-10 1.007
Clinical Stage T2 vs. RL (0.213, 1.196) 0.120
T3 0.505
Distant Metastasis VEGF 0-1 vs. RL (0.264, 1.326) 0.200
2-3 0.592
Age < 71 vs. RL (0.813, 6.614) 0.120
≥71 2.318
Combined Gleason Score 2-6 vs. RL (1.622,61.105) 0.013†
7-10 9.957
Clinical Stage T2 vs. RL (0.376, 3.580) 0.800
T3 1.160
Local Progression VEGF 0-1vs. RL (0.321, 2.064) 0.660
2-3 0.814
Age < 71 vs. RL (0.288, 3.515) 0.990
≥71 1.006
Combined Gleason Score 2-6 vs. RL (0.420, 9.427) 0.390
7-10 1.990
Clinical Stage T2 vs. RL (0.146, 1.755) 0.280
T3 0.506
Disease-free Survival VEGF 0-1vs. RL (0.273, 0.995) 0.048†
2-3 0.521
Age < 71 vs. RL (0.807, 3.601) 0.162
≥ 71 1.705
Combined Gleason Score 2-6 vs. RL (0.792, 4.567) 0.150
7-10 1.902
Clinical Stage T2 vs. RL (0.403, 2.054) 0.052
T3 0.910
Biochemical Failure VEGF 0-1vs. RL (0.251, 1.170) 0.120
2-3 0.542
Age < 71 vs. RL (0.805, 3.834) 0.160
≥ 71 1.757
Combined Gleason Score 2-6 vs. RL (0.783, 14.343) 0.100
7-10 3.352
Clinical Stage T2 vs. RL (0.425, 3.151) 0.780
T3 1.157
RT Alone Arm(n = 58) Endpoints Covariate Comparison HR* 95% CI p-value**
Overall Survival VEGF 0-1 vs. RL (0.622, 2.028) 0.699
2-3 1.123
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Table 3 Multivariate proportional hazards models by treatment arm (Continued)
Age < 71 vs. RL (0.890, 2.800) 0.118
≥ 71 1.579
Combined Gleason Score 2-6 vs. RL (0.839, 2.566) 0.178
7-10 1.468
Clinical Stage T2 vs. RL (0.760, 2.917) 0.246
T3 1.489
Distant Metastasis VEGF 0-1 vs. RL (0.777, 3.319) 0.200
2-3 1.606
Age < 71 vs. RL (0.422, 1.706) 0.640
≥71 0.848
Combined Gleason Score 2-6 vs. RL (0.992, 3.825) 0.053
7-10 1.947
Clinical Stage T2 vs. RL (0.357, 1.789) 0.590
T3 0.800
Local Progression VEGF 0-1vs. RL (0.670, 2.669) 0.410
2-3 1.337
Age < 71 vs. RL (0.391, 1.643) 0.540
≥71 0.801
Combined Gleason Score 2-6 vs. RL (0.259, 1.067) 0.075
7-10 0.525
Clinical Stage T2 vs. RL (0.415, 1.971) 0.800
T3 0.905
Disease-free Survival VEGF 0-1vs. RL (0.779, 2.371) 0.279
2-3 1.359
Age < 71 vs. RL (0.305, 0.979) 0.042†
≥ 71 0.547
Combined Gleason Score 2-6 vs. RL (1.021, 3.537) 0.043†
7-10 1.900
Clinical Stage T2 vs. RL (0.473, 1.913) 0.889
T3 0.952
Biochemical Failure VEGF 0-1vs. RL (0.815, 2.562) 0.210
2-3 1.446
Age < 71 vs. RL (0.315, 1.104) 0.056
≥ 71 0.565
Combined Gleason Score 2-6 vs. RL (0.655, 2.356) 0.510
7-10 1.242
Clinical Stage T2 vs. RL (0.474, 2.459) 0.850
T3 1.080
* A hazard ratio (HR) is defined as the ratio of the estimated hazard for those with a variable value 1 to the estimated hazard for those with a variable value 0. A
hazard ratio of 1 indicates no difference between two subgroups.
** P-values from Chi-square test using Cox (overall survival and disease-free survival) or Fine & Gray (distant metastasis, local progression, and biochemical failure)
Proportional Hazards Model.
† indicates the statistically significant at the significance level of 0.05.
1 patient without Gleason score is not included.
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and predictive value, comparable molecular markers are
not available for men with a diagnosis of prostate cancer.
Through these molecular markers, appropriate targeted
therapy may be selected for patients at a higher risk of
cancer progression who will benefit from treatment and
avoiding the side effects of therapy from those who will
not benefit. Thus, the search for a biomarker of similar
utility in prostate cancer is of great importance. A recent
review of classical and novel biomarkers as prognostic
factors for prostate cancer has highlighted the poor quality
and heterogeneity of studies to date, with generally no
conclusive results thus far [39].
VEGF is a potent angiogenic factor involved in tumor
angiogenesis and represents a potential therapeutic target.
Published data regarding VEGF expression in prostate
carcinoma has been conflicting. Previous studies in the
literature have reported markedly varied VEGF expression
in prostate carcinoma, ranging generally from 40% to
100% [18-28]. There are limited, even fewer, studies on
the prognostic and predictive value of VEGF expression in
prostate cancer, also with controversial results [31-34].
In the present study, which is among the largest studies
of VEGF expression in prostate cancer with a long-term
follow-up of 12.2 years, we explored the potential value
of VEGF as a prognostic and predictive biomarker among
men with locally advanced prostate cancer enrolled on
RTOG 8610. In this study, we found no statistically sig-
nificant correlation between the intensity of VEGF ex-
pression (0–1) and (2–3) for overall survival, distant
metastasis, local progression, disease-free survival, or
biochemical failure. The results remain non-significant
when adjusted for other covariates. There is also no
VEGF Intensity Score (0-1)
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Figure 1 Univariate proportional hazards regression analysis
for overall survival.
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Figure 3 Univariate proportional hazards regression analysis
for local progression.
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Figure 2 Univariate proportional hazards regression analysis
for distant metastasis.
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Figure 4 Univariate proportional hazards regression analysis
for disease-free survival.
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statistically significant predictive value of VEGF demon-
strated comparing the treatment arms.
These results are consistent with recent works such as
that by Concato et al. [31] who investigated molecular
markers of cell cycle regulation and angiogenesis and
death from prostate cancer. The authors found that
there is immunohistochemical evidence of association
of bcl-2, p53, or high microvessel density in prostate
cancer biopsy specimens at diagnosis and an increased
long-term risk of death from prostate cancer. However,
there was no statistically significant association with
VEGF. A study by Strohmeyer et al. [40] also found the
importance of microvessel density. In particular, they
noted that a high microvessel density was a negative
prognostic factor for tumor progression and had a
predictive value higher than the classical characteristics
of clinical stage, grade, and PSA in prostate cancer after
radical prostatectomy. On the contrary, previous reports in
the literature by Peyromaure et al. [32] found that VEGF
expression in prostate cancer tissue was associated with
the risk of cancer progression after radical prostatectomy.
Furthermore, Shariat and colleagues [33] reported that
preoperative plasma VEGF was independently associated
with metastases to lymph nodes and biochemical progres-
sion after radical prostatectomy, and Vergis and colleagues
[34] found that increased expression of VEGF and
HIF-1alpha were noted in patients at high risk of bio-
chemical failure. It is also interesting to note that Mori
and colleagues [41] have recently suggested prognostic
value for VEGF-A and VEGF-C expression levels in
that higher VEGF-A expression was associated with
improved overall survival and high VEGF-C expression
was associated with decreased risk of developing clinical
recurrence. They examined gene expression levels using
quantitative real-time PCR. It also differed from our study
in that it represented a post prostatectomy setting while
our study population consisted of patients treated
with primary radiation therapy. The findings of increased
VEGF levels in the castrate disease population may
suggest that tumor cells acquire new alterations that
enable them to survive in the castrated state (adaptation),
or represent the outgrowth of rare, pre-existing cells
capable of surviving hormonal therapy (selection). The pa-
tient population of RTOG 8610 represents a locally-
advanced disease population with bulky tumors. The role
of elevated VEGF levels in the castrate resistant popula-
tion may reflect an adaption response, as these patients
are on long-term (life) androgen deprivation therapy. The
paper by Mori and colleagues [41] evaluated short-term
androgen deprivation therapy in a preoperative vs. post-
operative setting. A possible difference in the findings
may be a function of duration of androgen deprivation
therapy in the respective patient populations.
There are a number of confounding factors and
limitations that may explain the conflicting results in the
literature of VEGF expression studies [18-28,31-34].
Firstly, the majority of these studies consist of retrospective
analyses of very small sample sizes with short follow-up.
Ideally, these studies should have long-term follow-up,
such as our present study, to examine endpoints such as
overall survival rather than biochemical failure. Secondly,
measurement of VEGF levels is often problematic, with
issues involving tissue availability, sample collection,
tissue processing, and storage techniques, all of which
could alter results [42]. In fact, in a study of renal
cell carcinoma, Jacobsen and colleagues [43] noted that
increased storage time resulted in decreased VEGF ex-
pression in the membranes of tumor cells from paraffin-
embedded tissue samples. Christensen and colleagues [42]
suggest that, for reliable and consistent results, the ideal
conditions for sample collection and preparation should
be identified in the study design phase. Then each aspect
of sample collection, processing, and storage should be
clearly specified in the standard operating procedure
document of the study. Thirdly, the level of sensitivity of
commonly used assays may be too low to detect meaning-
ful changes in VEGF expression, as even small changes in
tumor VEGF expression may be clinically significant de-
pending on the level of dependence of the tumor on
VEGF signaling [44]. Furthermore, the lack of significance
as found in this study may be due to the tissue sample size
and homogeneity of the patient group. Lastly, there is no
consensus in the literature of a “gold standard” VEGF de-
tection assay, and there is a lack of a predefined, accepted,
clinically meaningful “cut-off” point for VEGF expression
assay measurements. The authors acknowledge that there
are other quantitative methods of evaluating VEGF such
as examining mRNA or gene expression levels; however,
at the time this analysis was performed, the IHC method
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Figure 5 Univariate proportional hazards regression analysis
for biochemical failure.
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was the RTOG “standard” at that time and continues to be
widely used. Examining the VEGF receptor may further
provide informative information in future studies.
In conclusion, the results of much research in VEGF
expression in human prostate cancer to date are
conflicting. Most studies are only exploratory or hypothesis
generating, with small patient numbers. There are even
fewer studies on the prognostic or predictive value of
VEGF in prostate cancer. Trials are often fraught with
inherent challenges as described above. Euphoria is now
somewhat tempered because often the initially reported
promising results are not reproducible.
In our present study, we found no statistically significant
prognostic or predictive value of VEGF expression for
locally advanced prostate cancer. This study is among
the larger studies of VEGF expression in prostate cancer,
and we urge the research community to avoid the
misrepresentation of the literature with a lack of pub-
lication of even well-designed large negative studies, a
publication bias against negative trials, as the current
literature in this area appears to be predominated by
only small exploratory positive trials, with a lack of
subsequent confirmation with larger, longer prospect-
ively designed trials. Thus, to date, the usefulness of
VEGF as a prognostic and predictive factor in pros-
tate cancer remains to be clarified. In this study, we
had the opportunity to evaluate VEGF levels in the
well-characterized RTOG 8610 patient population.
There have been a number of other biomarker studies
done in this patient population already, and this study
complements what is known for this patient popula-
tion [45-51]. However, with the limitations presented,
we acknowledge that this secondary analysis of RTOG
8610 will not serve to make the definitive statement
regarding whether VEGF is a useful biomarker or not,
but reporting on this well-characterized patient population
with long-term follow-up and numerous other biomarker
publications arising from this population is in our opinion
a significant contribution to the current heterogeneous
VEGF literature [18-28,31-34].
There is an urgent need to establish multidisciplinary
initiatives for coordinating further research in the area
of human prostate cancer biomarkers, and ultimately
strive towards improving the treatment of prostate cancer
patients through better targeted therapy.
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